● Home ● Random ● Nearby ● Log in ● Settings ● Donate ● About Wikipedia ● Disclaimers

Retatrutide

● Article ● Talk ● Language ● Watch ● Edit

Retatrutide (LY-3437943) is an experimental drug for obesity developed by American pharmaceutical company Eli Lilly and Company. It is a triple hormone receptor agonist of GLP-1, GIP, and GCGR receptors.^[1] It has been shown to achieve a more than 17.5% mean weight reduction in adults without diabetes but with obesity or preobesity (overweight) during a phase 2 trial.^[2]^[3]^[4]

Retatrutide
Clinical data

Other names	LY-3437943
Identifiers
IUPAC name L-tyrosyl-2-methylalanyl-L-glutaminylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-alpha -aspartyl-L-tyrosyl-L-seryl-L-isoleucyl-2-methyl-L-leucyl-Lleucyl-L-alpha -aspartyl-L-lysyl-N6-(N-(19-carboxy-1-oxononadecyl)-L-gamma-glutamyl-2-(2-(2-aminoethoxy)ethoxy)acetyl)-L-lysyl-L-alanyl-L-glutaminyl-2-methylalanyl-L-alanyl-Lphenylalanyl-L-isoleucyl-L-alpha -glutamyl-L-tyrosyl-L-leucyl-L-leucyl-L-alpha -glutamylglycylglycyl-L-prolyl-L-seryl-L-serylglycyl-L-alanyl-L-prolyl-L-prolyl-L-prolyl-L-serinamide
CAS Number	2381089-83-2
UNII	NOP2Y096GV
ChEMBL	ChEMBL5095485
Chemical and physical data
Formula	C₂₂₃H₃₄₃F₃N₄₆O₇₀
Molar mass	4845.444 g·mol⁻¹

Chemistry

edit

The drug is a peptide with amino acid sequence YA1QGTFTSDYSIL2LDKK4AQA1AFIEYLLEGGPSSGAPPPS3.^[5]

References

edit

^ Coskun T, Urva S, Roell WC, Qu H, Loghin C, Moyers JS, et al. (September 2022). "LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept". Cell Metabolism. 34 (9): 1234–1247.e9. doi:10.1016/j.cmet.2022.07.013. PMID 35985340. S2CID 251675508.

^ "Lilly's phase 2 retatrutide results published in The New England Journal of Medicine show the investigational molecule achieved up to 17.5% mean weight reduction at 24 weeks in adults with obesity and overweight" (Press release). Eli Lilly. 26 June 2023. Retrieved 3 July 2023.

^ Constantino, Annika Kim (26 June 2023). "Eli Lilly experimental obesity drug could beat rivals in total weight loss for patients". CNBC. Retrieved 3 July 2023.

^ Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S, et al. (June 2023). "Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial". The New England Journal of Medicine. 389 (6): 514–526. doi:10.1056/NEJMoa2301972. PMID 37366315. S2CID 259260926. Free access subject to registration.

^ "Compound Report Card". www.ebi.ac.uk. n.d.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Retatrutide&oldid=1234025457" Last edited on 12 July 2024, at 05:36

Languages

●Deutsch ●Русский

●This page was last edited on 12 July 2024, at 05:36 (UTC). ●Content is available under CC BY-SA 4.0 unless otherwise noted. ●Privacy policy ●About Wikipedia ●Disclaimers ●Contact Wikipedia ●Code of Conduct ●Developers ●Statistics ●Cookie statement ●Terms of Use ●Desktop